Clinical trial
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in…
NCT00235755 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00235755 |
|---|---|
| Title | Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures |
| Acronym | RESTORE2 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | Bausch Health Americas, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Seizures |
| Intervention type | Drug |
| Interventions | Retigabine, Placebo |
| Enrollment | 539 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Oct 10, 2005 |
| Last update posted | Apr 21, 2017 |
| Countries | Australia, Belgium, France, Germany, Hungary, Israel, Poland, Russia, South Africa, Spain, Ukraine, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: